Tuesday, January 08, 2008

Albendazole for lymphatic filariasis. Part 2


A compare of albendazole and vesper detected no burden on
microfilariae generality (920 participants; 3 trials); one run (499
participants) reported significantly lower microfilariae compactness at
six months.
Albendazole performed slightly worse than ivermectin in two trials (436
participants).
Compared with diethylcarbamazine (DEC), two body part trials (56
participants) found little change in microfilariae figure over an
extended follow up.
One larger attempt (502 participants) found a statistically significant
force for DEC at six months, but none at triad months.

Microfilariae generality and spacing were statistically
significantly lower with the unit of albendazole and ivermectin
compared with ivermectin alone in two of digit trials (649
participants).
Two trials compared albendazole plus DEC with DEC alone and found no
statistically significant conflict in microfilariae ratio, though one
tribulation favoured the mathematical process at six months (relative
risk 0.62, 95% hopefulness musical notation 0.32 to 1.21; 491
participants).
This visitation also found a statistically significant decrease in
microfilariae compactness.

There
is insufficient grounds to confirm or refute that albendazole co –
administered with DEC or ivermectin is more effective than DEC or
ivermectin alone in freeing microfilariae or ending individual worms.
Albendazole combined with ivermectin appears to have a body part
outcome on microfilaraemia, but this was not consistently demonstrated.
This is a part of article Albendazole for lymphatic filariasis. Part 2 Taken from "Albendazole (Generic Albenza) Information" Information Blog

No comments: